COMMUNIQUÉS West-GlobeNewswire

Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
16/09/2026
NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and [...]
Grey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD $1.1 Million
16/09/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: [...]
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
16/09/2026
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
Coave Therapeutics Strengthens Leadership Team to Advance Lead Gene Therapy Program into the Clinic
16/09/2026
Senior appointments add world-class expertise across gene therapy development, ophthalmology, CMC, regulatory affairs and global operations to support the next phase of growth Carl De Luca, PhD, appointed Chief [...]
Sironax Announces Option Exercise and Asset Purchase
16/09/2026
Novartis exercises option to acquire Sironax’s brain delivery platform Sironax to advance three clinical-stage programs and multiple early-stage candidates using purchase proceeds Sironax to retain development rights to [...]
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
16/09/2026
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
Shock Top and Spirit Halloween Brew Up a Scary Good Collaboration
16/09/2026
Limited-Edition Candy Corn Wheat Ale Craft Beer and Spirit Halloween-Exclusive Wedgehead Costume Bring Big Flavor, Big Fun, and Head-Turning Halloween Energy to Fans Nationwide PORTLAND, Ore., Sept. 16, 2026 (GLOBE [...]
AAVantgarde to Showcase Clinical Progress in Usher 1B and Stargardt Disease at EURetina 2026
16/09/2026
MILAN, Sept. 16, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its proprietary dual-AAV [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/09/2026
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases [...]
Kailera Therapeutics to Participate in September Investor Conferences
16/09/2026
WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced [...]
Abalos Therapeutics Publishes Two Articles in Viruses Further Validating its AdaptInnate Approach to Treat Solid Tumors
16/09/2026
Preclinical findings further strengthen the scientific foundation for Abalos’ AdaptInnate approach, which leverages systemically administered non-lytic arenaviruses to selectively target solid tumors by triggering body- [...]
Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy – including THEO-260 in Advanced Ovarian Cancer – at Upcoming Investor and Scientific Events
16/09/2026
Oxford, UK, September 16, 2026 – Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that members of its senior leadership team will participate in a [...]
EIB and Angelini Ventures’ Partnership Reaches €48.5 Million in Investments
16/09/2026
Rome, 16 September 2026 New €17 million investment into MMI, a microsurgery robotics company, marks the third investment completed under the €150 million partnership in less than 12 months, following ADCytherix and [...]
UpFront Diagnostics Announces CE Mark Approval for LVOne — the World's First Rapid Blood Test to Diagnose Stroke
16/09/2026
LVOne is the only blood-based diagnostics kit for stroke diagnosis to be CE certified CAMBRIDGE, United Kingdom, Sept. 16, 2026 (GLOBE NEWSWIRE) -- UpFront Diagnostics has announced CE mark approval for LVOne—the world' [...]
UpFront Diagnostics obtient le marquage CE pour LVOne, premier test sanguin rapide au monde destiné au diagnostic de l’AVC
16/09/2026
LVOne est le seul kit de diagnostic sanguin destiné au diagnostic de l’AVC à avoir obtenu le marquage CE CAMBRIDGE, Royaume-Uni, 16 sept. 2026 (GLOBE NEWSWIRE) -- UpFront Diagnostics annonce l’obtention du marquage CE [...]
Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026
16/09/2026
New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy® pill, Wegovy® [...]
EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)
16/09/2026
Late Breaking Oral Presentation at 26th EURETINA Congress, 1-4 October 2026, Vienna PARIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing [...]
First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.
16/09/2026
September 16, 2026 News Release First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study. COPENHAGEN, DENMARK, September 16 , 2026 – BioPorto A/S (“ [...]
TME PHARMA CEO MESSAGE
16/09/2026
TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for [...]

Pages